Phase I study of the heparanase inhibitor roneparstat: An innovative approach for multiple myeloma therapy

Haematologica

Volumn 103, Issue 10, 2018, Pages e469-e472

  Galli, Monica ^a   Chatterjee, Manik ^b   Grasso, Mariella ^c   Specchia, Giorgina ^d   Magen, Hila ^e   Einsele, Hermann ^b   Celeghini, Ivana ^c   Barbieri, Paola ^f   Paoletti, David ^f   Pace, Silvia ^g   Sanderson, Ralph D ^h   Rambaldi, Alessandro ^a,i   Nagler, Arnon ^e  

^a PAPA GIOVANNI XXIII HOSPITAL   (Italy)

^b UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^c S CROCE E CARLE HOSPITAL   (Italy)

^d POLICLINICO   (Italy)

^e SHEBA MEDICAL CENTER   (Israel)

^f Leadiant Biosciences SA   (Switzerland)

^g Research Development   (Italy)

^h UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

ⁱ UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ENZYME INHIBITOR; HEPARIN; HEPARIN LYASE; RONEPARSTAT; TUMOR PROTEIN;

AGED; CLINICAL TRIAL; ENZYMOLOGY; FEMALE; HUMAN; MALE; METABOLISM; MIDDLE AGED; MULTIPLE MYELOMA; PHASE 1 CLINICAL TRIAL; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ENZYME INHIBITORS; FEMALE; HEPARIN; HEPARIN LYASE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM PROTEINS;

EID: 85053128287     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2017.182865     Document Type: Letter

References (14)

1. Kawano Y, Moschetta M, Manier S, Glavey S, et al. Targeting the bone marrow microenvironment in multiple myeloma. Immunol Rev. 2015;263(1):160-172.
2. Vlodavsky I, Singh P, Boyango I, et al. Heparanase: from basic research to therapeutic applications in cancer and inflammation. Drug Resist Updat. 2016;29:54-75.
3. Sanderson RD, Elkin M, Rapraeger AC, Ilan N, Vlodavsky I. Heparanase regulation of cancer, autophagy and inflammation: new mechanisms and targets for therapy. FEBS J. 2017;284(1):42-55.
4. Masola V, Secchi MF, Gambaro G, Onisto M. Heparanase as a target in cancer therapy. Curr Cancer Drug Targets. 2014;14(3):286-293.
5. Kelly T, Miao HQ, Yang Y, et al. High heparanase activity in multiple myeloma is associated with elevated microvessel density. Cancer Res. 2003;63(24):8749-8756.
6. Yang Y, Yaccoby S, Liu W, et al. Soluble syndecan-1 promotes growth of myeloma tumors in vivo. Blood. 2002;100(2):610-617.
7. Yang Y, Macleod V, Miao HQ, et al. Heparanase enhances syndecan-1 shedding: a novel mechanism for stimulation of tumor growth and metastasis. J Biol Chem. 2007;282(18):13326-13333.
8. Purushothaman A, Chen L, Yang Y, Sanderson RD. Heparanase stimulation of protease expression implicates it as a master regulator of the aggressive tumor phenotype in myeloma. J Biol Chem. 2008; 283(47):32628-32636.
9. Ramani VC, Vlodavsky I, Ng M, et al. Chemotherapy induces expression and release of heparanase leading to changes associated with an aggressive tumor phenotype. Matrix Biol. 2016;55:22-34.
10. Ramani VC, Zhan F, He J, et al. Targeting heparanase overcomes chemoresistance and diminishes relapse in Myeloma. Oncotarget. 2016;7(2):1598-1607.
11. Naggi A, Casu B, Perez M, et al. Modulation of the heparanaseinhibiting activity of heparin through selective desulfation, graded Nacetylation, and glycol splitting. J Biol Chem. 2005;280(13):12103-12113.
12. Pala D, Rivara S, Mor M, et al. Kinetic analysis and molecular modeling of the inhibition mechanism of roneparstat (SST0001) on human heparanase. Glycobiology. 2016;26(6):640-654.
13. Ritchie JP, Ramani VC, Ren Y, et al. SST0001, a chemically modified heparin, inhibits myeloma growth and angiogenesis via disruption of the heparanase/syndecan-1 axis. Clin Cancer Res. 2011;17(6):1382-1393.
14. Nobili L, Goegan M, Pezzetta D, Pace S, Barbieri P, Molinari A. Validation of a homogeneous fluorescence quenching assay for the direct quantification of a heparin-like compound in human plasma. EBF. November 19-21, 2014; abstract.